Optos plc has the vision to be The Retina Company and recognised as a leading provider of devices to eyecare professionals for improved patient care. Optos’ core devices produce ultra-widefield (UWF™), high resolution digital images (optomap®) of approximately 82% and 200◦ of the retina, something no other device is capable of doing in any single image. An optomap image provides a bigger picture and more clinical information which facilitates the early detection, management and effective treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy and age-related macular degeneration. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as hypertension and certain cancers.
Optos has a range of retinal imaging devices that support different customer segments and patient needs such as wellness screening carried out by optometrists in primary care settings or more exacting imaging in secondary care practices that are clinically managing a patient base with advanced ocular disease. Our most advanced imaging devices for disease management and treatment support ophthalmologists and retinal specialists in the medical care market.
The latest products, Daytona and California represents the newest generation of Optos ultra-widefield retinal imaging technology and have been converted to desktop models while still providing high resolution images. For both devices, the ergonomic body is designed to increase patient comfort, as well as make it easier to correctly position the eye for image capture. All image modalities; colour, red-free and autofluorescence (AF) are included in both devices. California features fluorescein angiography (FA) and our newest UWF imaging modality, indocyanine green angiography. ICG is used for imaging the choroidal vasculature which is important for the diagnosis, management and treatment of certain conditions such as neovascular age-related macular degeneration (AMD) and disorders with choroidal neovascular membranes.
Optos also offers optical coherence tomography (“OCT”) devices and optical ultrasound scanners, used in the diagnosis and management of eye disease and systemic conditions. OCT delivers an image that shows a three dimensional, cross-sectional view of the retina in the central area of the retina around the optic nerve and macula and is used to detect the presence of and understand the severity of disease, determine treatment approaches and monitor post-treatment effect. Currently under product development is an ultra-widefield retinal imaging device combined with OCT. This united device has the potential to offer ophthalmologists and optometrists the most powerful tools for disease diagnosis, monitoring and management.
Optos is committed to utilising the latest technology to manufacture new products and software that support optomap as a standard of care therefore helping eyecare professionals around the world save sight and lives. Furthermore the company continues to strengthen its clinical evidence and expand its disease indications to demonstrate the importance of imaging the entire retina.